Wegovy 2.4mg Injection

Q1: What is Wegovy 2.4mg used for?

Wegovy 2.4mg is the maximum maintenance dose for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity.

Q2: How much weight can I lose with Wegovy 2.4mg?

In the STEP-1 trial, adults using Wegovy 2.4mg with lifestyle changes lost an average of 15% of their body weight over 68 weeks. Patients with the highest BMI or strongest adherence to lifestyle changes often achieve 20% or more.

Q3: How long do I have to take Wegovy 2.4mg?

Wegovy is a long-term treatment. Weight tends to return after stopping. Most patients who benefit from Wegovy will need to continue it indefinitely to maintain weight loss, similar to how blood pressure medications work long-term.

Q4: Is Wegovy 2.4mg covered by insurance?

Coverage varies by insurer and country. In some markets, Wegovy is covered for patients meeting specific BMI and comorbidity criteria. Contact your insurer or healthcare provider for coverage details in your region.

Q5: Can I drink alcohol while on Wegovy 2.4mg?

Alcohol is not strictly contraindicated but can worsen GI side effects and contribute to caloric intake that counteracts weight loss. Heavy drinking should be avoided; light to moderate intake should be discussed with your prescriber.

Q6: Does Wegovy 2.4mg cause muscle loss?

Weight loss with any agent involves some loss of lean mass. Adding resistance exercise to your routine significantly reduces the proportion of muscle lost. Some research supports that semaglutide-induced weight loss may preserve lean mass better than very low-calorie diets alone.

Q7: What happens if I stop Wegovy 2.4mg?

Most patients regain approximately two-thirds of their lost weight within 1–2 years after stopping. Appetite and metabolic setpoints tend to return to baseline. Discontinuation should be planned with your prescriber, not done abruptly.

Q8: Can Wegovy 2.4mg improve heart health?

Yes. The SELECT trial showed a 20% reduction in MACE (heart attack, stroke, cardiovascular death) in overweight/obese adults with established cardiovascular disease using semaglutide 2.4mg, independent of glycaemic effects.

Q9: What medications interact with Wegovy 2.4mg?

Semaglutide can affect absorption of oral medications by slowing gastric emptying. Oral contraceptives, levothyroxine, and other time-sensitive oral drugs should be taken consistently. Discuss all medications with your prescriber at the time of initiating Wegovy.

Q10: Is there a biosimilar version of Wegovy available?

As of 2025, branded Wegovy from Novo Nordisk remains the primary approved product in most markets. Regulatory-approved biosimilars of semaglutide may become available in coming years; confirm current availability with your prescriber or pharmacist.